Chimeric antigen receptor T cell therapy for multiple myeloma
Abstract Chimeric antigen receptor (CAR) T cell therapy is a new cancer immunotherapy targeting cancer-specific cell surface antigen. CD19-CAR T cells have been already shown to be very effective to B cell leukemia/lymphoma. Now, many researchers are developing CAR T cells for multiple myeloma. CAR...
Saved in:
Main Authors: | Kana Hasegawa (Author), Naoki Hosen (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2019-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Integrins in multiple myeloma
by: Naoki Hosen
Published: (2020) -
Characterization of novel dual tandem CD19/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma
by: Liqing Kang, et al.
Published: (2020) -
The Past, Present, and Future of Clinically Applied Chimeric Antigen Receptor-T-Cell Therapy
by: Yuki Fujiwara, et al.
Published: (2022) -
The FDA's Regulatory Framework for Chimeric Antigen Receptor‐T Cell Therapies
by: Peter Marks
Published: (2019) -
Biomarkers in individualized management of chimeric antigen receptor T cell therapy
by: Mengyi Du, et al.
Published: (2020)